Table 1.
Characteristics of participants in SPIROMICS and the MESA Lung Study
| SPIROMICS (n=2853) | MESA Lung (n=2949) | |
|---|---|---|
|
| ||
| Age - years | 63.0 ± 9.2 | 69.4 ± 9.3 |
| Male sex - no. (%) | 1515 (53.1%) | 1417 (48.1%) |
| Race/ethnicity, no. (%) | ||
| White | 2087 (74.1%) | 1123 (38.1%) |
| Black | 550 (19.3%) | 803 (27.2%) |
| Hispanic | 148 (5.2%) | 631 (21.4%) |
| Asian | 33 (1.2%) | 392 (13.3%) |
| Height - m | 1.7 ± 0.1 | 1.65 ± 0.10 |
| Weight - kg | 80.9 ± 18.0 | 78.1 ± 17.4 |
| BMI - kg/m2 | 28.0 ± 5.3 | 28.4 ± 5.4 |
| Smoking status - no. (%) | ||
| Never | 198 (6.9%) | 1341 (45.8%) |
| Former | 1609 (56.4%) | 1371 (46.8%) |
| Current | 1046 (36.7%) | 219 (7.5%) |
| Pack-years, among ever-smokers - median | 43.0 | 14.5 |
| (IQR) | (31.0, 60.0) | (3.0, 33.0) |
| FEV1, percent-predicted | 75.1 ± 26.7 | 94.9 ± 22.9 |
| FVC, percent-predicted | 91.7 ± 18.0 | 97.2 ± 22.5 |
| FEV1/FVC | 0.59 ± 0.16 | 0.74 ± 0.09 |
| COPD – no. (%) | 1760 (61.7%) | 446 (16.9%) |
| GOLD 1 | 380 (21.6%) | 239 (53.6%) |
| GOLD 2 | 787 (44.8%) | 182 (40.8%) |
| GOLD 3 | 412 (23.5%) | 25 (5.6%) |
| GOLD 4 | 178 (10.1%) | 0 |
| Total lung volume - ml | 5871 ± 1454 | 4791 ± 1283 |
| Percent emphysema - % | 7.5 ± 10.1 | 2.5 ± 3.3 |
| Traditional emphysema subtype - no.(%)* | ||
| Centrilobular emphysema | 804 (93.7) | 530 (18.0) |
| Panlobular emphysema | 44 (5.1) | 90 (3.1) |
| Paraseptal emphysema | 754 (88.0) | 384 (13.0) |
| Airway wall thickness - mm | 1.44 ± 0.42 | 1.02 ± 0.24 |
| Diasynapsis (CT-assessed airway-to-lung ratio) | 0.032 ± 0.004 | 0.033 ± 0.004 |
| Small airway count (N) | -- | 30.8 ± 14.9 |
| Interstitial lung abnormalities - no. (%)* | 252 (25.3) | 276 (12.1) |
| Total Pulmonary Vascular Volume Percent | 2.91 ± 0.36 | 2.70 ± 0.27 |
Abbreviations: BMI=Body mass index, IQR=Interquartile range, FEV1=Forced expiratory volume in 1 second, FVC=Forced vital capacity, COPD=Chronic obstructive pulmonary disease, GOLD=Global initiative for chronic obstructive lung disease.
*
Traditional emphysema subtypes and interstitial lung abnormalities read in SPIROMICS for a subset of 804–857 and 999 participants, respectively